Evolution of bone mineral density in AIDS patients on treatment with zidovudine/lamivudine plus abacavir or lopinavir/ritonavir

HIV Medicine

Volumn 9, Issue 2, 2008, Pages 89-95

  Rivas, Pablo ^a   Gorgolas M ^b   Garcia Delgado R ^b   Diaz Curiel M ^b   Goyenechea, A ^b   Fernandez Guerrero M L ^b  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

Adverse effects; Bones; Highly active antiretroviral therapy; HIV; Osteoporosis

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; BODY WEIGHT; BONE DENSITY; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CORRELATION ANALYSIS; DRUG INDUCED DISEASE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMUR NECK; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OSTEOLYSIS; OSTEOPENIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RADIUS; SIDE EFFECT;

ABSORPTIOMETRY, PHOTON; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BONE DENSITY; CASE-CONTROL STUDIES; DIDEOXYNUCLEOSIDES; FEMUR NECK; HIV INFECTIONS; HUMANS; LAMIVUDINE; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRIMIDINONES; RITONAVIR; ZIDOVUDINE;

EID: 38949161165     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2007.00525.x     Document Type: Article

References (25)

1. Paton NI, Macallan DC, Griffin GE, Pazianas M. Bone mineral density in patients with human immunodeficiency virus infection. Calcif Tissue Int 1997; 61: 30-32.
2. Loiseau-Peres S, Delaunay C, Poupon S et al. Osteopenia in patients infected by the human immunodeficiency virus. A case-control study. Joint Bone Spine 2002; 69: 482-485.
3. Annapoorna N, Rao GV, Reddy NS, Rambabu P, Rao KR. An increased risk of osteoporosis during acquired immunodeficiency syndrome. Int J Med Sci 2004; 1: 152-164.
4. Glesby MJ. Bone disorders in human immunodeficiency virus infection. Clin Infect Dis 2003; 37 (Suppl. 2): S91-S95.
5. Pan G, Yang Z, Ballinger SW, McDonald JM. Pathogenesis of osteopenia/ osteoporosis induced by highly active anti-retroviral therapy for AIDS. Ann NY Acad Sci 2006; 1068: 297-308.
6. Amorosa V, Tebas P. Bone disease and HIV infection. Clin Infect Dis 2006; 42: 108-114.
7. Nolan D, Upton R, McKinnon E et al. Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS 2001; 15: 1275-1280.
8. McDermott AY, Terrin N, Wanke C, Skinner S, Tchetgen E, Shevitz AH. CD4 + cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: A longitudinal study. Clin Infect Dis 2005; 41: 1662-1670.
9. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: A meta-analytic review. AIDS 2006; 20: 2165-2174.
10. Qaqish RB, Sims KA. Bone disorders associated with the human immunodeficiency virus: Pathogenesis and management. Pharmacotherapy 2004; 24: 1331-1346.
11. Bruera D, Luna N, David DO, Bergoglio LM, Zamudio J. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS 2003; 17: 1917-1923.
12. Jain RG, Lenhard JM. Select HIV protease inhibitors alter bone and fat metabolism ex vivo. J Biol Chem 2002; 277: 19247-19250.
13. Pan G, Kilby M, McDonald JM. Modulation of osteoclastogenesis induced by nucleoside reverse transcriptase inhibitors. AIDS Res Hum Retroviruses 2006; 22: 1131-1141.
14. Gallant JE, Staszewski S, Pozniak AL et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial. JAMA 2004; 292: 191-201.
15. Dube MP, Qian D, Edmondson-Melancon H et al. Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy. Clin Infect Dis 2002; 35: 475-481.
16. Fernandez-Rivera J, Garcia R, Lozano F et al. Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients. HIV Clin Trials 2003; 4: 337-346.
17. Mondy K, Yarasheski K, Powderly WG et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis 2003; 36: 482-490.
18. Mallon PW, Miller J, Cooper DA, Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS 2003; 17: 971-979.
19. Williams FM, Cherkas LF, Spector TD, MacGregor AJ. The effect of moderate alcohol consumption on bone mineral density: A study of female twins. Ann Rheum Dis 2005; 64: 309-310.
20. Clowes JA, Riggs BL, Khosla S. The role of the immune system in the pathophysiology of osteoporosis. Immunol Rev 2005; 208: 207-227.
21. Serrano S, Marinoso ML, Soriano JC et al. Bone remodelling in human immunodeficiency virus-1-infected patients. A histomorphometric study. Bone 1995; 16: 185-191.
22. Teichmann J, Stephan E, Lange U et al. Osteopenia in HIV-infected women prior to highly active antiretroviral therapy. J Infect 2003; 46: 221-227.
23. Brown TT, Ruppe MD, Kassner R et al. Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia. J Clin Endocrinol Metab 2004; 89: 1200-1206.
24. Wiercinska-Drapalo A, Jaroszewicz J, Tarasow E, Siergiejczyk L, Prokopowicz D. The possible association between serum cholesterol concentration and decreased bone mineral density as well as intravertebral marrow fat in HIV-1 infected patients. Infection 2007; 35: 46-48.
25. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services, October 10, 2006; 1-113. http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf (accessed May 7, 2007).